Back to search results

Measuring Acute Drug Demand in Opioid Use Disorder

This study is looking at how suvorexant, an FDA-approved medication for insomnia, might affect the desire for and use of other drugs in people with Opioid Use Disorder (OUD). You would stay overnight at the University of Maryland, Baltimore for about 14-16 days. During this time, you would receive suvorexant or a placebo (an inactive substance) and also take different blinded study medications (Drug A, Drug B, Drug C, Drug D). Researchers will measure how much you want these drugs and how much you might use them. The study aims to enroll 75 participants aged 18-65 who meet criteria for moderate or severe OUD and are in good general health.

Study design
This is an interventional study with an unclear status, planning to enroll 75 participants. It involves a double-blinded approach, meaning neither you nor the researchers will know if you are receiving suvorexant or a placebo, or which blinded study medication you are taking.
What's involved
You would have a screening visit, followed by an approximate 14 to 16-day inpatient (overnight) stay. During this stay, you will receive daily oral study medications and provide feedback.
Compensation
Not stated in the trial record.
Follow-up
Primary outcomes are measured upon completion of experimental sessions, which occur approximately 8 hours after drug administration, and after Experimental Session 4.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05829655

Measuring Acute Drug Demand in Humans

Recruiting
EARLY_PHASE1Ages 18–65InterventionalBasic science
University of Maryland, Baltimore
~75 participants
Updated 2026-06-23 on ClinicalTrials.gov
What's tested:Drug A (Blinded Drug)Drug B (Blinded Drug)Drug C (Blinded Drug)Drug D (Blinded Drug)Suvorexant (20mg/day)Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Demand Intensity
Measured over Upon completion of experimental session (~8 hours post drug administration)
+2 more outcomes measured

Conditions

Opioid Use Disorder
Opioid Dependence

Explore related trials

Opioid DependenceOpioid Use Disorder

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Justin Strickland, PhD · PRINCIPAL_INVESTIGATOR · University of Maryland, Baltimore

Who to contact

Justin Strickland, PhD
[email protected]
667-354-3516
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age between 18 and 65 years old
Meets Diagnostic and Statistical Manual-5 criteria for Opioid Use Disorder (OUD) (moderate or severe)
Lifetime substance use history criterion \[blinded\]
Medically cleared to take suvorexant and blinded study medications
Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests

Exclusion

Pregnant or breast feeding
Seeking opioid use treatment
Significant mental health or physical disorder that is expected to interfere with study participation as assessed by the study physicians or medical staff
Known contraindications or allergies to suvorexant and/or the blinded study medications

What this trial measures

  • Demand IntensityUpon completion of experimental session (~8 hours post drug administration)

    Consumption of blinded drug at unconstrained price as measured by an incentivized demand task. Minimum value is 0, maximum value is not constrained. Higher scores indicate more drug consumption at unconstrained price (a worse outcome).

  • Demand ElasticityUpon completion of experimental session (~8 hours post drug administration)

    Changes in blinded drug consumption with changes in price as measured by an incentivized demand task. There is no minimum or maximum value. Higher scores indicate greater drug price sensitivity (a better outcome).

  • Cross-Price ElasticityAfter Experimental Session 4

    Change in consumption of price-fixed good based on change in price of price varying good. Positive values indicate a substitute, negative values indicate a complement, and zero values indicate an independent commodity.